Technical Analysis for RNN - Rexahn Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 1.38 9.52% 0.12
RNN closed up 9.52 percent on Thursday, January 17, 2019, on 3.94 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical RNN trend table...

Date Alert Name Type % Chg
Jan 17 Expansion Breakout Bullish Swing Setup 0.00%
Jan 17 Pocket Pivot Bullish Swing Setup 0.00%
Jan 17 Volume Surge Other 0.00%
Jan 17 Wide Range Bar Range Expansion 0.00%
Jan 17 Upper Bollinger Band Walk Strength 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Above Upper BB Strength 0.00%
Jan 17 Upper Bollinger Band Touch Strength 0.00%
Jan 16 Calm After Storm Range Contraction 9.52%
Jan 16 Upper Bollinger Band Walk Strength 9.52%

Older signals for RNN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system disorders, sexual dysfunction, and other medical needs. Its clinical stage oncology candidates comprise Archexin, an inhibitor of the protein kinase Akt-1, which has completed a Phase IIa clinical trial for the treatment of pancreatic cancer, as well as is focusing on initiating Phase IIa clinical trials for chemo-resistant solid tumors and hematological malignancies; RX-3117, which has completed an exploratory Phase I clinical study in humans with therapeutic potential in a range of cancers, including colon, lung, and pancreatic cancer; and RX-5902, a small molecule that inhibits the phosphorylation of p68 RNA helicase and focuses on initiating Phase I clinical trials. The company's pre-clinical pipeline consist of RX-0201-Nano, a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, a nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101, nano-polymer anticancer. It has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; Revaax Pharmaceuticals LLC; and Rexgene Biotech Co., Ltd. The company is based in Rockville, Maryland.
Is RNN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.7
52 Week Low 0.85
Average Volume 299,012
200-Day Moving Average 1.5261
50-Day Moving Average 1.0767
20-Day Moving Average 1.0393
10-Day Moving Average 1.1135
Average True Range 0.1059
ADX 31.28
+DI 36.9452
-DI 6.1744
Chandelier Exit (Long, 3 ATRs ) 1.1623
Chandelier Exit (Short, 3 ATRs ) 1.1677
Upper Bollinger Band 1.2988
Lower Bollinger Band 0.7798
Percent B (%b) 1.16
BandWidth 49.937458
MACD Line 0.0492
MACD Signal Line 0.0004
MACD Histogram 0.0488
Fundamentals Value
Market Cap 39.27 Million
Num Shares 28.5 Million
EPS -1.01
Price-to-Earnings (P/E) Ratio -1.37
Price-to-Sales 0.00
Price-to-Book 3.65
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.77
Resistance 3 (R3) 1.76 1.62 1.71
Resistance 2 (R2) 1.62 1.52 1.63 1.68
Resistance 1 (R1) 1.50 1.46 1.56 1.51 1.66
Pivot Point 1.36 1.36 1.39 1.37 1.36
Support 1 (S1) 1.24 1.26 1.30 1.25 1.10
Support 2 (S2) 1.10 1.20 1.11 1.08
Support 3 (S3) 0.98 1.10 1.06
Support 4 (S4) 0.99